Novartis India downgraded to strong sell amid valuation concerns
pre-market1 source ↓written by the desknot a recommendation
Novartis India has been downgraded to strong sell due to valuation concerns. The stock's P/E ratio is 215.7, and its P/B ratio is 2.71, indicating a premium valuation. The PEG ratio of 1.70 raises sustainability concerns, while the dividend yield of 2.94% may not justify the high valuation compared to peers like Ajanta Pharma and Gland Pharma.
Not investment advice. For informational purposes only.